S Warrier
Overview
Explore the profile of S Warrier including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
31
Citations
300
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Agas R, Fahey M, Gosavi R, Kong J, Tan J, Chu J, et al.
Clin Oncol (R Coll Radiol)
. 2024 Dec;
37():103692.
PMID: 39662100
Aims: While systemic management of high risk colon cancer is well addressed, advances in local management remain incremental. This study aims to identify a group of colon cancer patients where...
2.
Dalli J, Nguyen C, Jindal A, Epperlein J, Hardy N, Pulitano C, et al.
JPRAS Open
. 2024 Mar;
40:32-47.
PMID: 38425697
Introduction: Immediate post-mastectomy breast reconstruction offers benefits; however, complications can compromise outcomes. Intraoperative indocyanine green fluorescence angiography (ICGFA) may mitigate perfusion-related complications (PRC); however, its interpretation remains subjective. Here, we...
3.
Sekaran S, Warrier S, Selvaraj V, Ganapathy D, Ramasamy P
Clin Oncol (R Coll Radiol)
. 2024 Feb;
36(5):e115-e117.
PMID: 38368227
No abstract available.
4.
Khan A, Laing E, Beaumont A, Warrier S, Riedel B, Heriot A
ANZ J Surg
. 2023 Jun;
93(6):1463-1464.
PMID: 37313969
No abstract available.
5.
Ofri A, Elstner K, Mann G, Kumar S, Warrier S
Surgeon
. 2023 Apr;
21(6):356-360.
PMID: 37088639
Breast cancer is the most common non-skin cancer in Australia, affecting 1 in 7 women by the age of 85 years. Current management of early breast cancer is becoming increasingly...
6.
Wilson K, Flood M, Narasimhan V, Pham T, Warrier S, Ramsay R, et al.
Eur J Surg Oncol
. 2021 Apr;
47(8):1862-1874.
PMID: 33814240
Background: Locally advanced rectal cancer is routinely treated with neo-adjuvant long course chemoradiotherapy or short course radiotherapy, followed by total mesorectal excision. Not all patients respond to this treatment and...
7.
Lau S, Kong J, Bell S, Heriot A, Stevenson A, Moloney J, et al.
Br J Surg
. 2021 Mar;
108(2):214-219.
PMID: 33711138
Background: Transanal total mesorectal excision (taTME) aims to overcome some of the technical challenges faced when operating on mid and low rectal cancers. Specimen quality has been confirmed previously, but...
8.
Rahme J, Rajkomar A, Larach J, Chauhan A, Smart P, Warrier S
Colorectal Dis
. 2020 Aug;
22(12):2345.
PMID: 32780504
No abstract available.
9.
Smith N, Murphy D, Lawrentschuk N, McCormick J, Heriot A, Warrier S, et al.
Tech Coloproctol
. 2020 Jul;
24(11):1145-1153.
PMID: 32662050
Background: Pelvic exenteration remains a viable and effective treatment option for the management of locally advanced or recurrent pelvic malignancy. The aim of this study was to present an early...
10.
Rahme J, Rajkomar A, Larach T, Smart P, Warrier S
Colorectal Dis
. 2020 Jul;
22(11):1804.
PMID: 32627951
No abstract available.